However, the invasive strategy did show lower cardiovascular mortality risk and higher non-cardiovascular mortality risk at 5.7-year follow-up
Extended follow-up of the ISCHEMIA randomized trial over a median of 5.7 years demonstrated no difference in all-cause mortality between an initial invasive strategy and an initial conservative strategy for patients with chronic coronary disease, and a lower risk of cardiovascular mortality and higher risk of non-cardiovascular mortality for the initial invasive strategy.